Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.62 |
| ▸ | CLK1 | P49759 | 2/20 | 0.55 |
| ▸ | CASR | P41180 | 1/20 | 0.55 |
| ▸ | ACP1 | P24666 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393148 | 0.94 | SLC27A1 (0.62) | SLC27A1CLK1GFERL3MBTL1CA1 | |
| SCHEMBL3393276 | 0.89 | SLC27A1 (0.74) | SLC27A1CLK1CA1CA2KDM4E | |
| SCHEMBL3396188 | 0.89 | SLC27A1 (0.64) | SLC27A1CLK1CA1CA2ALDH1A1 | |
| SCHEMBL3394423 | 0.89 | CLK1 (0.67) | SLC27A1CLK1CASRACP1CA1 | |
| SCHEMBL3392183 | 0.87 | CLK1 (0.65) | SLC27A1CLK1CA1CA2ALDH1A1 | |
| SCHEMBL3398024 | 0.86 | ALDH1A1 (0.72) | CASRKDM4EALDH1A1 | |
| SCHEMBL3397006 | 0.86 | CASR (0.58) | CASRACP1KDM4EALDH1A1 | |
| SCHEMBL3394225 | 0.85 | KDM4E (0.71) | CLK1CASRACP1CA1CA2 | |
| SCHEMBL8358629 | 0.85 | SLC27A1 (0.63) | SLC27A1CLK1GFERL3MBTL1 | |
| SCHEMBL13497073 | 0.84 | USP2 (0.58) | CLK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | claimed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| EP-2024364-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007137417-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007137417-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, CACNA1I | SLC27A1 3163/4885CLK1 3714/4885CASR 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.